CT45A1 and colorectal carcinoma: Thus, clinical grade ROCK‐inhibiting agents may be applied in the regional MSI‐H TME along with ICBT to enhance the cytotoxic efficacy and lower the cost and treatment frequency of adoptive NK cell transfer therapy in aggressive CT45A1(+) MSI‐H CRC patients.